United Therapeutics (UTHR) CEO Rothblatt Sells $5.2M of Stock

CEO Martine Rothblatt Sells UTHR Shares

United Therapeutics Corporation Chairperson and CEO Martine Rothblatt sold 9,500 shares of the company stock on June 16, 2026. The transaction was executed at an average price of $549.80 per share, bringing the total value of the sale to approximately $5.22 million. According to regulatory filings with the SEC, the move was carried out under a pre-arranged trading plan.

Recent Insider Activity Pattern

This transaction fits into a broader pattern of regular stock sales and acquisitions by the chief executive. Earlier in June 2026, Rothblatt executed several transactions involving blocks of 9,500 shares, including purchases valued between $1.29 million and $1.32 million on June 22, June 25, and June 26, alongside other planned sales such as a $5.1 million sale on October 14, 2026. Insider sales are common executive actions and do not necessarily signal a change in the company's outlook.

United Therapeutics Stock and Valuation

United Therapeutics Corporation shares trade on the NasdaqGS under the ticker UTHR. On the day of publication, the stock changed hands near $551.47, sitting comfortably within its 52-week range of $409.07 to $609.35. The biotechnology company has a market capitalization of $21.15 billion, a price-to-earnings ratio of 17.67, and a forward P/E ratio of 16.42.

Analysts Set New Price Targets

Wall Street analysts maintain varied outlooks on United Therapeutics following recent rating adjustments. RBC Capital maintains an Outperform rating with a price target of $708.00, while Morgan Stanley holds an Equal-Weight rating with a $566.00 target. BTIG recently upgraded the stock to a Buy rating with a $728.00 price target, whereas Goldman Sachs initiated coverage with a Sell rating and a $321.00 target. Overall, the consensus leans toward a buy recommendation across twelve analyst opinions.

About United Therapeutics

United Therapeutics Corporation is a healthcare company based in Silver Spring, Maryland. Founded in 1996, the drug manufacturer focuses on developing and commercializing specialty treatments for chronic and life-threatening conditions, including pulmonary arterial hypertension and neuroblastoma, alongside organ xenotransplantation research.

What to Watch Next for UTHR

Investors will look toward the company's next financial results report, scheduled for October 28, 2026, for further updates on revenue and earnings. United Therapeutics reported $3.15 billion in revenue over the trailing period with a net margin of 41.56% and a return on equity of 19.32%.